Tests toripalimab with chemotherapy for recurrent nasopharyngeal cancer
Tests toripalimab with chemotherapy in people with nasopharyngeal cancer that has returned.
Plain-language title generated from the registry record
Registry title: A Study of Toripalimab in Combination With Cisplatin and Gemcitabine in Participants With Recurrent Metastatic Nasopharyngeal Cancer
Key facts
- Where
- Toronto, CanadaSee the site
- Phase
- Phase 4
AI summary: who the study is looking for
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for people with recurrent or metastatic nasopharyngeal cancer who have not had systemic treatment for it. They would get toripalimab with chemotherapy.
- Age
- 12 years and older
- Sex
- All sexes can join.
- Disease stage
- Nasopharyngeal cancer that has come back or spread (stage IV-B), confirmed by tissue or cell tests, with disease that can be measured on scans. EBV-positive and EBV-negative cancers can both join.
- Earlier treatment
- No earlier systemic therapy for recurrent or metastatic disease. If the cancer came back after treatment meant to remove all of it, more than 6 months must have passed since the last radiotherapy or chemotherapy.
- Biomarker or test result
- EBER/EBV-negative or EBER/EBV-positive cancer, with or without HPV.
Main reasons for not taking part
- Disease that can be treated with local therapy meant to remove all of it
- Cancer that came back within 6 months of chemoradiation meant to remove all of it
- Rapidly progressing disease, such as tumor bleeding or uncontrolled tumor pain
- Active or untreated cancer spread to the brain or its membranes (CNS)
Read by machine on 12 November 2026.
Where in Canada
- Princess Margaret Cancer CentreToronto, CanadaContact: Arundhati ShuklaTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorTrial details
- Who runs it
- Coherus Oncology, Inc.
- Trial code
- NCT06457503
- Record updated
- 30 July 2026
- Original description
This study aims to investigate toripalimab with chemotherapy in participants with nasopharyngeal cancer.Read full original descriptionShow less
Single-Arm Study of Toripalimab in Combination With Cisplatin and Gemcitabine in Recurrent Metastatic Nasopharyngeal Carcinoma Systemic Treatment Naïve Participants
This study aims to investigate toripalimab with chemotherapy in participants with nasopharyngeal cancer.
Inclusion: Histological or cytological confirmation of recurrent/metastatic nasopharyngeal cancer with either EBV or non-EBV-associated cancer. The following subgroups are included:; EBER/EBV-negative (HPV+/-); EBER/EBV-positive (HPV+/-); Recurrent/metastatic (stage IV-B as defined by the International Union against Cancer [UICC] and American Joint Committee on Cancer [AJCC] staging system for nasopharyngeal cancer [NPC], eighth edition) or recurrent NPC after curative treatment. For recurrent NPC, more than 6 months between the last dose of radiotherapy or chemotherapy and the date of recurrence; Measurable disease based on RECIST v 1.1 as determined by the site. Note: Lesions situated in a previously irradiated area are considered measurable if progression has been demonstrated in such lesions.
Exclusion: Prior systemic therapy administered in the recurrent or metastatic setting. Participants who develop disease recurrence within 6 months from curative intent chemoradiation will be excluded; Active or untreated central nervous system (CNS) metastases (e.g., brain or leptomeningeal), as determined on computerized tomography (CT) or magnetic resonance imaging (MRI) evaluation during screening and prior radiographic assessments. Participants who have prior therapies for brain or leptomeningeal metastasis and have been stabilized ≥ 1 month and have discontinued systemic steroid therapy (>10 mg/day prednisone or equivalent) ≥ 1 month prior to enrollment are eligible; Other protocol-defined inclusion and exclusion criteria apply; Disease that is suitable for local therapy administered with curative intent; Rapidly progressing disease (e.g., tumor bleeding, uncontrolled tumor pain) in the opinion of the treating investigator.